p95HER2 expression in HER2-positive breast cancer with primary resistance

被引：0

作者：

Goh, Chih Wan ^{[1
,2
,3
]}

Yang, Benlong ^{[1
,2
]}

Chi, Yayun ^{[1
,2
]}

Wu, Jiong ^{[1
,2
,4
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China

[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China

[3] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr Xiamen, Xiamen, Fujian, Peoples R China

[4] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai 200032, Peoples R China

来源：

PRECISION MEDICAL SCIENCES | 2024年 / 13卷 / 02期

基金：

中国国家自然科学基金;

关键词：

breast cancer; molecular targeted therapy; trastuzumab; CARBOXY-TERMINAL FRAGMENT; HER2; RECEPTOR; TRASTUZUMAB; LAPATINIB; PROTEIN; BENEFIT; GROWTH;

D O I：

10.1002/prm2.12128

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

p95HER2 isoform is a truncated form of HER2 that retains the C terminal domain but lacks an N terminal trastuzumab binding site. From 2014 to 2016, we assessed the expression of p95HER2 expression in 59 HER2-positive breast cancer patients from FUSCC. The median follow-up was 54 months. In our study, 19 patients (32.2%) were p95HER2 positive. p95HER2-positive expression rate is higher in premenopausal patients than in postmenopausal patients (68.4% vs. 31.6%, P = .026). p95HER2 positive was found more in premenopausal patients and was associated with worse DFS (hazard ratio, 2.21; 95% CI, 1.06-4.61; P = .034), indicating that p95HER2 expression tends to be a more aggressive isoform type of HER2-positive breast cancer.

引用

页码：99 / 106

页数：8

共 27 条

[1] Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 [J].

Abraham, Jame ;

Montero, Albert J. ;

Jankowitz, Rachel C. ;

Salkeni, Mohamad Adham ;

Beumer, Jan H. ;

Kiesel, Brian F. ;

Piette, Fanny ;

Adamson, Laura M. ;

Nagy, Rebecca J. ;

Lanman, Richard B. ;

Sperinde, Jeff ;

Huang, Weidong ;

Allegra, Carmen J. ;

Srinivasan, Ashok ;

Wang, Ying ;

Pogue-Geile, Katherine L. ;

Lucas, Peter C. ;

Jacobs, Samuel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) :2601-+

[2]

[Anonymous], 2011, J Clin Oncol

[3]

Christianson TA, 1998, CANCER RES, V58, P5123

[4] High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance) [J].

Chumsri, Saranya ;

Sperinde, Jeff ;

Liu, Heshan ;

Gligorov, Joseph ;

Spano, Jean-Philippe ;

Antoine, Martine ;

Aspitia, Alvaro Moreno ;

Tan, Winston ;

Winslow, John ;

Petropoulos, Christos J. ;

Chenna, Ahmed ;

Bates, Michael ;

Weidler, Jodi Marie ;

Huang, Weidong ;

Dueck, Amylou ;

Perez, Edith A. .

CLINICAL CANCER RESEARCH, 2018, 24 (13) :3053-3058

[5] Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab [J].

Duchnowska, Renata ;

Sperinde, Jeff ;

Czartoryska-Arlukowicz, Bogumila ;

Mysliwiec, Paulina ;

Winslow, John ;

Radecka, Barbara ;

Petropoulos, Christos ;

Demlova, Regina ;

Orlikowska, Marlena ;

Kowalczyk, Anna ;

Lang, Istvan ;

Ziolkowska, Barbara ;

Debska-Szmich, Sylwia ;

Merdalska, Monika ;

Grela-Wojewoda, Aleksandra ;

Zawrocki, Anton ;

Biernat, Wojciech ;

Huang, Weidong ;

Jassem, Jacek .

ONCOTARGET, 2017, 8 (61) :104149-104159

[6] Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff [J].

Duchnowska, Renata ;

Sperinde, Jeff ;

Chenna, Ahmed ;

Haddad, Mojgan ;

Paquet, Agnes ;

Lie, Yolanda ;

Weidler, Jodi M. ;

Huang, Weidong ;

Winslow, John ;

Jankowski, Tomasz ;

Czartoryska-Arlukowicz, Bogumila ;

Wysocki, Piotr J. ;

Foszczynska-Kloda, Malgorzata ;

Radecka, Barbara ;

Litwiniuk, Maria M. ;

Zok, Jolanta ;

Wisniewski, Michal ;

Zuziak, Dorota ;

Biernat, Wojciech ;

Jassem, Jacek .

CLINICAL CANCER RESEARCH, 2014, 20 (10) :2805-2813

[7] Breast Cancer, Version 3.2022 [J].

Gradishar, William J. ;

Moran, Meena S. ;

Abraham, Jame ;

Aft, Rebecca ;

Agnese, Doreen ;

Allison, Kimberly H. ;

Anderson, Bethany ;

Burstein, Harold J. ;

Chew, Helen ;

Dang, Chau ;

Elias, Anthony D. ;

Giordano, Sharon H. ;

Goetz, Matthew P. ;

Goldstein, Lori J. ;

Hurvitz, Sara A. ;

Isakoff, Steven J. ;

Jankowitz, Rachel C. ;

Javid, Sara H. ;

Krishnamurthy, Jairam ;

Leitch, Marilyn ;

Lyons, Janice ;

Mortimer, Joanne ;

Patel, Sameer A. ;

Pierce, Lori J. ;

Rosenberger, Laura H. ;

Rugo, Hope S. ;

Sitapati, Amy ;

Smith, Karen Lisa ;

Smith, Mary Lou ;

Soliman, Hatem ;

Stringer-Reasor, Erica M. ;

Telli, Melinda L. ;

Ward, John H. ;

Wisinski, Kari B. ;

Young, Jessica S. ;

Burns, Jennifer ;

Kumar, Rashmi .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (06) :691-722

[8] Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy [J].

Lluis Parra-Palau, Josep ;

Morancho, Beatriz ;

Peg, Vicente ;

Escorihuela, Marta ;

Scaltriti, Maurizio ;

Vicario, Rocio ;

Zacarias-Fluck, Mariano ;

Pedersen, Kim ;

Pandiella, Atanasio ;

Nuciforo, Paolo ;

Serra, Violeta ;

Cortes, Javier ;

Baselga, Jose ;

Perou, Charles M. ;

Prat, Aleix ;

Rubio, Isabel T. ;

Arribas, Joaquin .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11)

[9] A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers [J].

Lluis Parra-Palau, Josep ;

Pedersen, Kim ;

Peg, Vicente ;

Scaltriti, Maurizio ;

Davide Angelini, Pier ;

Escorihuela, Marta ;

Mancilla, Sandra ;

Sanchez Pla, Alexandre ;

Ramon y Cajal, Santiago ;

Baselga, Jose ;

Arribas, Joaquin .

CANCER RESEARCH, 2010, 70 (21) :8537-8546

[10] Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients [J].

Maria, Alaa Mohamed ;

El-Shebiney, Mohamed ;

El-Saka, Ayman Mohamed ;

Zamzam, Yomna .

JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (02) :49-55

← 1 2 3 →